D

EDGC

245620KOSDAQ자연과학 및 공학 연구개발업

37.5 / 100

Reference Date: 2026-04-13

Financial Score7.5 / 40
News Sentiment5.0 / 25
Momentum10.0 / 20
Disclosure15.0 / 15
AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Roughly flat over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

EDGC is a global bio-genomics big data company established in 2013 as a joint venture between a Korean medical institution and the U.S.-based Diagnomics, Inc. It offers key services such as NGS-based genomic analysis, personalized diagnostic tests, and liquid biopsy (OncoCatch), along with its flagship services 'YouWho' for genetic ancestry analysis and 'NICE' for non-invasive prenatal testing. In 2021, EDGC acquired a Canadian health supplement manufacturer to expand its customized health supplement business, aiming to develop integrated precision medicine solutions through genomic-based drug development.

Number of Employees

63people

Average Salary

43.6M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 81.314.0Point
PBR
13.06Industry Average 3.050.0Point

4.3x industry avg (risky)

ROE
-209.61Industry Average -31.713.5Point

6.6x industry avg (excellent)

Debt Ratio
2964.47Industry Average 46.060.0Point

64.4x industry avg (risky)

Trend 2022~20240.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼35.8% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼16.6% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -150.7% (declining, 2yr)

Detailed News Sentiment

1 totalPositive 0Neutral 0Negative 1Average Sentiment Score 20

Detailed Momentum

52-week position4.0Point

52w mid range (50%)

Current 415Won52-week high 41552-week low 415
1-month return3.0Point

1m 0% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

13 totalPositive 4Neutral 8Negative 1
  • Neutral[기재정정]최대주주변경2026-04-10
  • Neutral사업보고서 (2025.12)2026-04-08
  • Neutral[기재정정]사업보고서 (2024.12)2026-04-07
  • Neutral주식등의대량보유상황보고서(일반)2026-03-30
  • Neutral사업보고서제출기한연장신고서 (2025.12)2026-03-24